Therefore, in this study, we used a PLGA (tumor antigen+adjuvant)-NP system in combination with PLGA (PD-L1 siRNA+PD-1 siRNA)-NPs to induce antigen-specific CD8+ T cell-based immune responses.22 The gene discussed is PDCD1; the disease is neoplasm.